COMPOSITIONS FOR TARGETING CONDUCTING AIRWAY CELLS COMPRISING ADENO-ASSOCIATED VIRUS CONSTRUCTS
    2.
    发明申请
    COMPOSITIONS FOR TARGETING CONDUCTING AIRWAY CELLS COMPRISING ADENO-ASSOCIATED VIRUS CONSTRUCTS 审中-公开
    用于引导包含腺相关病毒构建物的导引气道细胞的组合物

    公开(公告)号:US20120046349A1

    公开(公告)日:2012-02-23

    申请号:US13266599

    申请日:2010-04-29

    摘要: An artificial AAV capsid comprising a heterologous conducting airway targeting sequence is provided. The artificial AAV is useful as a targeting moiety, for delivery of heterologous molecules which are associated therewith. The artificial AAV is also useful in the generation of AAV vectors having the artificial capsid. Also described are methods of modifying the native tropism and transduction efficiency of vectors by improving and/or ablating their ability to transduce conducting airway cells. Methods of targeting conducting airway cells and delivering therapeutic and other molecules thereto are also provided.

    摘要翻译: 提供了包含异源导管气道靶向序列的人造AAV衣壳。 人造AAV可用作靶向部分,用于递送与其相关的异源分子。 人造AAV也可用于产生具有人造衣壳的AAV载体。 还描述了通过改善和/或消除其转导导管气道细胞的能力来改变载体的天然向性和转导效率的方法。 还提供了靶向导管气道并递送治疗剂和其它分子的方法。

    Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer
    3.
    发明申请
    Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer 有权
    改变组织特异性和改善AAV9介导的基因转移的组合物和方法

    公开(公告)号:US20130323226A1

    公开(公告)日:2013-12-05

    申请号:US13985630

    申请日:2012-02-17

    摘要: A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and a penultimate β-galactose residue. The modification may involve retargeting the vector by temporarily functionally ablate AAV9 binding in a subset of cells, thereby redirecting the vector to another subset of cells. Alternatively, the modification may involve increasing cellular update efficiency by treating the cells with a neuraminidase to expose cell surface β-galactose. Also provided are compositions containing the AAV9 vector and a neuraminidase. Also provided is a method for purifying AAV9 using β-galactose linked to solid support. Also provided are mutant vectors which have been modified to alter their targeting specificity, including mutant AAV9 in which the galactose binding domain is mutated and AAV in which an AAV9 galactose binding domain is engineered.

    摘要翻译: 描述了改变具有包含AAV9细胞表面结合结构域的衣壳的腺相关病毒(AAV)病毒载体的靶向和/或细胞摄取效率的方法。 该方法包括修饰进化枝F细胞表面受体,其包含具有末端唾液酸残基的聚糖和倒数第二半乳糖残基。 该修饰可能涉及通过临时功能地消融细胞子集中的AAV9结合来重新定向载体,从而将载体重定向到另一个细胞亚群。 或者,修饰可以涉及通过用神经氨酸酶处理细胞以暴露细胞表面β-半乳糖来增加细胞更新效率。 还提供了含有AAV9载体和神经氨酸酶的组合物。 还提供了使用与固体支持物连接的β-半乳糖来纯化AAV9的方法。 还提供已被修饰以改变其靶向特异性的突变载体,包括其中半乳糖结合结构域突变的突变AAV9和其中AAV9半乳糖结合结构域被工程化的AAV。